Tech Company Financing Transactions
Mahana Therapeutics Funding Round
Gurnet Point Capital, JAZZ Venture Partners and KKCG participated in a $61 million Series B capital raise for Mahana Therapeutics. The financing was announced on 8/12/2021.
Transaction Overview
Company Name
Announced On
8/12/2021
Transaction Type
Venture Equity
Amount
$61,000,000
Round
Series B
Investors
Gurnet Point Capital (Lead Investor)
JAZZ Venture Partners (Lead Investor)
Proceeds Purpose
The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana� IBS and accelerate development of several digital therapeutics for chronic health conditions.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Market Spear Tower 36th Floor
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Overview
Mahana Therapeutics is a digital therapeutics company. Digital therapeutics are treatment options that use internet- and mobile-based technologies to improve clinical outcomes, quality of life and well-being.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Basta
Chief Marketing Officer
Soren Mills
Chief Technical Officer
Simon Levy
VP - Finance
Myla Puyat
VP - Marketing
Kelly Price
VP - Operations
Adam Hardin
VP - Product Management
Ann Montgomery
VP - Regulatory Affairs
Kendal Dinsmore
Browse more venture capital transactions:
Prev: 8/12/2021: Tessian venture capital transaction
Next: 8/12/2021: AviaGames venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs